SG11201705646XA - Benzodiazepine dimers, conjugates thereof, and methods of making and using - Google Patents
Benzodiazepine dimers, conjugates thereof, and methods of making and usingInfo
- Publication number
- SG11201705646XA SG11201705646XA SG11201705646XA SG11201705646XA SG11201705646XA SG 11201705646X A SG11201705646X A SG 11201705646XA SG 11201705646X A SG11201705646X A SG 11201705646XA SG 11201705646X A SG11201705646X A SG 11201705646XA SG 11201705646X A SG11201705646X A SG 11201705646XA
- Authority
- SG
- Singapore
- Prior art keywords
- conjugates
- making
- methods
- benzodiazepine dimers
- benzodiazepine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103157P | 2015-01-14 | 2015-01-14 | |
| US201562215928P | 2015-09-09 | 2015-09-09 | |
| PCT/US2016/013136 WO2016115191A1 (en) | 2015-01-14 | 2016-01-13 | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705646XA true SG11201705646XA (en) | 2017-08-30 |
Family
ID=55305072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705646XA SG11201705646XA (en) | 2015-01-14 | 2016-01-13 | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9527871B2 (en) |
| EP (1) | EP3245213B1 (en) |
| JP (1) | JP6498773B2 (en) |
| KR (1) | KR20170102980A (en) |
| CN (1) | CN107428780B (en) |
| AU (1) | AU2016206798A1 (en) |
| BR (1) | BR112017014599A2 (en) |
| CA (1) | CA2973354A1 (en) |
| CL (1) | CL2017001824A1 (en) |
| CO (1) | CO2017008078A2 (en) |
| EA (1) | EA201791550A1 (en) |
| ES (1) | ES2783624T3 (en) |
| IL (1) | IL253402A0 (en) |
| MX (1) | MX2017009145A (en) |
| PE (1) | PE20171184A1 (en) |
| SG (1) | SG11201705646XA (en) |
| TW (1) | TW201632531A (en) |
| WO (1) | WO2016115191A1 (en) |
| ZA (1) | ZA201704738B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201632532A (en) * | 2015-01-14 | 2016-09-16 | 必治妥美雅史谷比公司 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
| US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| WO2018053552A2 (en) * | 2016-09-19 | 2018-03-22 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| AU2017343565A1 (en) * | 2016-10-10 | 2019-05-30 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
| CN116554262A (en) * | 2017-01-25 | 2023-08-08 | 伊缪诺金公司 | Process for preparing cytotoxic benzodiazepine derivatives |
| US20180346488A1 (en) * | 2017-04-20 | 2018-12-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| WO2019036433A2 (en) | 2017-08-16 | 2019-02-21 | Bristol-Myers Squibb Company | Prodruggable antibodies, prodrugs thereof, and methods of use and making |
| GB201714115D0 (en) | 2017-09-04 | 2017-10-18 | Femtogenix Ltd | Cytotoxic agents |
| CN116999572A (en) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | Antibody-drug conjugate, pharmaceutical composition and application thereof in preparation of drugs for treating tumors |
| AU2019276833A1 (en) | 2018-05-29 | 2020-11-26 | Intocell, Inc. | Novel benzodiazepine derivatives and uses thereof |
| BR112021008354A2 (en) * | 2018-10-31 | 2021-08-03 | Intocell, Inc. | fused heterocyclic benzodiazepine derivatives and uses thereof |
| SG11202104993SA (en) | 2018-11-14 | 2021-06-29 | Daiichi Sankyo Co Ltd | Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate |
| SI3886914T1 (en) | 2018-11-30 | 2023-06-30 | Bristol-Myers Squibb Company | Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses |
| CN113544155A (en) | 2018-12-12 | 2021-10-22 | 百时美施贵宝公司 | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| TW202102225A (en) | 2019-03-25 | 2021-01-16 | 日商第一三共股份有限公司 | Anti-HER2 antibody-pyrrolobenzodiazepine derivative conjugate |
| US20220168440A1 (en) | 2019-03-25 | 2022-06-02 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine deprivative conjugate |
| KR20210143839A (en) | 2019-03-27 | 2021-11-29 | 다이이찌 산쿄 가부시키가이샤 | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and PARP inhibitor |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| US20240115720A1 (en) | 2021-01-13 | 2024-04-11 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
| CN113372245B (en) * | 2021-06-17 | 2023-01-13 | 仪征市海帆化工有限公司 | Synthetic method of N-benzoyl-O, O-p-toluenesulfonyl-diethanolamine |
| WO2023037237A1 (en) * | 2021-09-09 | 2023-03-16 | Wavelength Enterprises Ltd | Process for the preparation of remimazolam |
| WO2023054706A1 (en) * | 2021-09-30 | 2023-04-06 | 味の素株式会社 | Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof |
| JPWO2023100829A1 (en) | 2021-11-30 | 2023-06-08 | ||
| TW202342106A (en) | 2022-02-09 | 2023-11-01 | 日商第一三共股份有限公司 | Environment-responsive masked antibodies and use thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2244210T3 (en) | 1998-08-27 | 2005-12-01 | Spirogen Limited | PIRROLOBENZODIAZEPINAS. |
| DK1545613T3 (en) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatin conjugates and their use in the treatment of cancer, an autoimmune disease or an infectious disease |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
| ES2381858T3 (en) | 2004-03-01 | 2012-06-01 | Spirogen Limited | 11-Hydroxy-5H-pyrrolo [2,1-C] [1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of C2 substituted pyrrolobenzodiazepines |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP1723152B1 (en) | 2004-03-09 | 2015-02-11 | Spirogen Sàrl | Pyrrolobenzodiazepines |
| DE602006011300D1 (en) | 2005-04-21 | 2010-02-04 | Spirogen Ltd | PYRROLOBENZODIAZEPINE |
| NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| ES2390476T3 (en) | 2005-12-08 | 2012-11-13 | Medarex, Inc. | Monoclonal antibodies against fucosil-GM1 and procedures for using anti-fucosil-GM1 |
| SI1813614T1 (en) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Cytotoxic agents comprising new tomaymycin derivatives |
| PL2178921T3 (en) | 2007-07-17 | 2016-06-30 | Squibb & Sons Llc | Monoclonal antibodies against glypican-3 |
| PT2019104E (en) | 2007-07-19 | 2013-12-03 | Sanofi Sa | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
| DK2195017T3 (en) | 2007-10-01 | 2015-01-19 | Bristol Myers Squibb Co | Human antibodies that bind mesothelin, and uses thereof |
| GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| KR102021728B1 (en) * | 2009-02-05 | 2019-09-16 | 이뮤노젠 아이엔씨 | Novel benzodiazepine derivatives |
| FR2949469A1 (en) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| ES2430567T3 (en) | 2010-04-15 | 2013-11-21 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| AU2011239522B2 (en) | 2010-04-15 | 2014-10-23 | Medimmune Limited | Targeted pyrrolobenzodiazapine conjugates |
| US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
| FR2963007B1 (en) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| PL2675479T3 (en) * | 2011-02-15 | 2016-09-30 | Cytotoxic benzodiazepine derivatives | |
| AU2012311505B2 (en) | 2011-09-20 | 2016-09-29 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
| WO2013053871A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines |
| EP2755642B1 (en) | 2011-10-14 | 2018-07-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| JP6399930B2 (en) | 2011-10-14 | 2018-10-03 | シアトル ジェネティクス，インコーポレーテッド | Pyrrolobenzodiazepine and target conjugates |
| WO2013055987A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| PL2839860T3 (en) | 2012-10-12 | 2019-10-31 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| SI2906248T1 (en) | 2012-10-12 | 2019-02-28 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CN105849086B (en) | 2012-11-24 | 2018-07-31 | 杭州多禧生物科技有限公司 | Hydrophily chain junctor and its application on drug molecule and cell-binding molecules conjugation reaction |
| US9562049B2 (en) | 2012-12-21 | 2017-02-07 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CN110627797A (en) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | Asymmetric pyrrolobenzodiazepine dimers for the treatment of proliferative and autoimmune diseases |
| US9821074B2 (en) | 2013-03-13 | 2017-11-21 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
| CN105142674B (en) | 2013-03-13 | 2018-11-13 | 麦迪穆有限责任公司 | Pyrrolobenzodiazepines Zhuo and its conjugate |
| JP2016518382A (en) | 2013-04-26 | 2016-06-23 | ピエール、ファーブル、メディカマン | Axl antibody drug conjugate and use thereof for the treatment of cancer |
-
2016
- 2016-01-13 PE PE2017001216A patent/PE20171184A1/en unknown
- 2016-01-13 WO PCT/US2016/013136 patent/WO2016115191A1/en active Application Filing
- 2016-01-13 CN CN201680006151.5A patent/CN107428780B/en active Active
- 2016-01-13 EA EA201791550A patent/EA201791550A1/en unknown
- 2016-01-13 US US14/994,296 patent/US9527871B2/en active Active
- 2016-01-13 SG SG11201705646XA patent/SG11201705646XA/en unknown
- 2016-01-13 KR KR1020177022244A patent/KR20170102980A/en not_active Application Discontinuation
- 2016-01-13 EP EP16703196.2A patent/EP3245213B1/en active Active
- 2016-01-13 TW TW105100987A patent/TW201632531A/en unknown
- 2016-01-13 BR BR112017014599A patent/BR112017014599A2/en not_active Application Discontinuation
- 2016-01-13 CA CA2973354A patent/CA2973354A1/en not_active Abandoned
- 2016-01-13 JP JP2017537227A patent/JP6498773B2/en active Active
- 2016-01-13 ES ES16703196T patent/ES2783624T3/en active Active
- 2016-01-13 MX MX2017009145A patent/MX2017009145A/en unknown
- 2016-01-13 AU AU2016206798A patent/AU2016206798A1/en not_active Abandoned
- 2016-11-15 US US15/351,843 patent/US9676794B2/en active Active
-
2017
- 2017-05-05 US US15/587,715 patent/US9822144B2/en active Active
- 2017-07-10 IL IL253402A patent/IL253402A0/en unknown
- 2017-07-13 CL CL2017001824A patent/CL2017001824A1/en unknown
- 2017-07-13 ZA ZA2017/04738A patent/ZA201704738B/en unknown
- 2017-08-10 CO CONC2017/0008078A patent/CO2017008078A2/en unknown
- 2017-10-17 US US15/785,675 patent/US10112975B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107428780A (en) | 2017-12-01 |
| JP2018503639A (en) | 2018-02-08 |
| PE20171184A1 (en) | 2017-08-22 |
| US9822144B2 (en) | 2017-11-21 |
| US9527871B2 (en) | 2016-12-27 |
| IL253402A0 (en) | 2017-09-28 |
| ES2783624T3 (en) | 2020-09-17 |
| US10112975B2 (en) | 2018-10-30 |
| KR20170102980A (en) | 2017-09-12 |
| US20170233436A1 (en) | 2017-08-17 |
| US20170073357A1 (en) | 2017-03-16 |
| US20160200742A1 (en) | 2016-07-14 |
| EP3245213A1 (en) | 2017-11-22 |
| MX2017009145A (en) | 2017-11-22 |
| CA2973354A1 (en) | 2016-07-21 |
| AU2016206798A1 (en) | 2017-08-31 |
| US9676794B2 (en) | 2017-06-13 |
| CO2017008078A2 (en) | 2017-11-10 |
| ZA201704738B (en) | 2019-02-27 |
| CL2017001824A1 (en) | 2018-02-09 |
| US20180079781A1 (en) | 2018-03-22 |
| EA201791550A1 (en) | 2017-11-30 |
| EP3245213B1 (en) | 2020-03-04 |
| WO2016115191A1 (en) | 2016-07-21 |
| TW201632531A (en) | 2016-09-16 |
| CN107428780B (en) | 2020-09-04 |
| JP6498773B2 (en) | 2019-04-10 |
| BR112017014599A2 (en) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201704738B (en) | Benzodiazepine dimers, conjugates thereof, and methods of making and using | |
| ZA201704739B (en) | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | |
| HUS2400014I1 (en) | Therapeutic antibodies and their uses | |
| HK1232140A1 (en) | Micro-organoids, and methods of making and using the same | |
| ZA201706040B (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| HK1248538A1 (en) | Cd48 antibodies and conjugates thereof | |
| HK1255483A1 (en) | Antibodies and immunoconjugates | |
| EP3355931C0 (en) | Protein conjugates | |
| IL252430A0 (en) | Antibodies, uses and methods | |
| IL272924A (en) | Methods for making and using endoxifen | |
| IL256462A (en) | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses | |
| HK1256368A1 (en) | Calicheamicin-antibody-drug conjugates and methods of use | |
| IL258759A (en) | Anti-cd3-folate conjugates and their uses | |
| ZA201704640B (en) | Silybin injection and preparation method therefor | |
| LT3661562T (en) | Method of conjugation of cys-mabs | |
| IL244857A0 (en) | Acetylcholinesterase-fc domain fusion protein | |
| AP2016001094S (en) | A-1 | |
| AU2015316V (en) | SUPA2221 Argyranthemum frutescens | |
| AU2015022V (en) | SUPA2235 Argyranthemum frutescens | |
| AU2015021V (en) | SUPA2220 Argyranthemum frutescens | |
| AU2015019V (en) | SUPA2101 Argyranthemum frutescens |